Evidence Hub

Efficacy of adding sildenafil to dapoxetine in treatment of dapoxetine non-responding mono-symptomatic premature ejaculation

Ahmed Ramadan, A. K. M. Koritenah, Mohamed Ibrahim AlMetwally AlGammal, Y. Badran

Al-Azhar International Medical Journal, 2024

200 participants

Abstract

Background: Primary premature ejaculation has been treated with selective serotonin reuptake inhibitors (SSRIs), however these medications have a low success rate, Aim: is to evaluate the efficacy and safety of adding sildenafil to dapoxetine for patients with premature, symptomatic ejaculation who did not respond to dapoxetine alone, Methods: This RCT was conducted at the urology outpatient centers of Al-Azhar University, Al-Hussein Hospital, and Sayed Galal Hospital. This research included 200 male patients with PE who were placed into two groups. For 8 weeks, 110 patients in Group A got sildenafil 50mg as an additional treatment to dapoxetine 30 mg. Group (B) consisted of 90 participants who received dapoxetine thirty milligrams with placebo for the same duration as group (A), Results: The study included 200 PE cases with no erectile dysfunction (ED). Group A showed an increased IIEF score and improved PE diagnostic tool results. Post-treatment intravaginal ejaculatory latency time (IVLT) was significantly changed among groups, with 48 patients in group A having a post-treatment IVLT of ≥ 4 minutes compared to 19 in group B. There were also significant differences in sex satisfaction scale after treatment, with 27.3% of patients in group A being extremely satisfied compared to 15.6% in group B, Conclusion: Dapoxetine and sildenafil combination treatment for patients with PE without ED appears to lengthen the patient's IVLT, IIEF score & sex satisfaction score, with…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free